Impact of High Risk Prognostic Parameters and Addition of Ibrutinib to Bendamustine/Rituximab (BR) on Outcomes for Patients with Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) from the Phase 3 Double-Blind HELIOS Trial Conference Paper uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Chanan-Khan, Asher
  • Cramer, Paula
  • Fraser, Graeme
  • Silva, Rodrigo Santucci
  • Grosicki, Sebastian
  • Pristupa, Aleksander
  • Dilhuydy, Marie Sarah
  • Goy, Andre
  • Mato, Anthony R
  • Damle, Rajendra
  • Phelps, Charles
  • Mahler, Michelle
  • Salman, Mariya
  • Schaffer, Michael
  • Howes, Angela
  • Balasubramanian, Sriram

publication date

  • December 3, 2015

published in